These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7107368)

  • 21. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
    Dische S; Saunders MI; Dunphy EP; Bennett MH; Des Rochers C; Stratford MR; Minchinton AI; Orchard RA
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.
    Workman P
    Br J Cancer; 1979 Sep; 40(3):335-53. PubMed ID: 508562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508.
    Coleman CN; Lee WW; Constine LS; Brown JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):431-4. PubMed ID: 6213588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testing of hypoxic cell radiosensitizers in vivo.
    Denekamp J
    Cancer Clin Trials; 1980; 3(2):139-48. PubMed ID: 7428137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.
    Akel G; Benard P; Canal P; Soula G
    Cancer Chemother Pharmacol; 1986; 17(2):121-6. PubMed ID: 3719893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new potent radiosensitizer: 1-(2',3'-dideoxy-alpha-D-erythro-hex-2'-enopyranosyl)-2-nitroimidazole (RA-263).
    Agrawal KC; Sakaguchi M; Rockwell S
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):403-7. PubMed ID: 7107358
    [No Abstract]   [Full Text] [Related]  

  • 27. [Radiosensitizing effect of a 2-nitroimidazole hydroxamate (KIN-804) to murine tumors].
    Tada T; Nakajima T; Onoyama Y; Nagasawa H; Hori H; Inayama S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1992 May; 52(5):688-90. PubMed ID: 1508643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trials of radiosensitizers: what should we expect?
    Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers.
    Brown JM; Yu NY
    Br J Radiol; 1980 Sep; 53(633):915-6. PubMed ID: 7437721
    [No Abstract]   [Full Text] [Related]  

  • 30. A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.
    Sasai K; Shibamoto Y; Takahashi M; Abe M; Wang J; Zhou L; Nishimoto S; Kagiya T
    Jpn J Cancer Res; 1989 Nov; 80(11):1113-8. PubMed ID: 2532634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro hypoxic cytotoxicity of nitroimidazoles: uptake and cell cycle phase specificity.
    Sutherland RM; Keng P; Conroy PJ; McDermott D; Bareham BJ; Passalacqua W
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):745-8. PubMed ID: 7107409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapy.
    Bernstein M; Gutin PH; Deen DF; Weaver KA; Levin VA; Barcellos MH
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):487-90. PubMed ID: 7107372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some aspects of the metabolism of misonidazole.
    Flockhart IR; Malcolm SL; Marten TR; Parkins CS; Ruane RJ; Troup D
    Br J Cancer Suppl; 1978 Jun; 3():264-7. PubMed ID: 277244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
    Timothy AR; Overgaard J; Overgaard M
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1765-8. PubMed ID: 6480460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiosensitization by a new potent nucleoside analog: 1-(1',3',4'-trihydroxy-2'-butoxy)methyl-2-nitroimidazole(RP-343).
    Murayama C; Suzuki A; Sato C; Tanabe Y; Shoji T; Miyata Y; Nishio A; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):433-43. PubMed ID: 8514541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
    Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers.
    Agrawal KC; Larroquette CA; Garg PK
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1301-5. PubMed ID: 6469754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiosensitization by 2-nitroimidazole nucleoside analog RP-170: radiosensitizing effects under both intravenous and oral administration.
    Murayama C; Suzuki A; Sato C; Tanabe Y; Miyata Y; Shoji T; Suzuki T; Sakaguchi M; Mori T
    Int J Radiat Oncol Biol Phys; 1992; 22(3):557-60. PubMed ID: 1531214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.
    Pedersen JE; Smith MR; Bugden RD; Peckham MJ
    Br J Cancer; 1979 Apr; 39(4):429-33. PubMed ID: 444398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo radiosensitizing effect of nitroimidazole derivative KIN-804.
    Tada T; Nakajima T; Onoyama Y; Murayama C; Mori T; Nagasawa H; Hori H; Inayama S
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):601-5. PubMed ID: 8005823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.